CRMP5 controls glioblastoma cell proliferation and survival through Notch-dependent signaling

Cancer Research

Volumn 75, Issue 17, 2015, Pages 3519-3528

  Moutal, Aubin ^a   Honnorat, Jérôme ^a   Massoma, Patrick ^a   Désormeaux, Pauline ^a   Bertrand, Caroline ^a   Malleval, Céline ^a   Watrin, Chantal ^a   Chounlamountri, Naura ^a   Mayeur, Marie Eve ^a   Besançon, Roger ^a   Naudet, Nicolas ^a   Magadoux, Léa ^a   Khanna, Rajesh ^b   Ducray, François ^a,c   Meyronet, David ^a,c   Thomasset, Nicole ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; NOTCH RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; DPYSL5 PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR XENOGRAFT; WESTERN BLOTTING; ADULT; AGED; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICE; MIDDLE AGED; NERVE TISSUE PROTEINS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942861700     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0631     Document Type: Article

References (51)

1. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, et al. Glioblastoma. In WHO Classification of Tumours of the Central Nervous System. DN Louis, H Ohgaki, OD Wiestler, WK Cavenee, Editors. Lyon, France: International Agency for Research on Cancer 2007, p. 33-49.
2. Badaoui N, Meyronet D, Cartalat-Carel S, Guyotat J, Jouanneau E, d'Hombres A, et al. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France. Rev Neurol 2014;170:222-7.
3. Helmy K, Halliday J, Fomchenko E, Setty M, Pitter K, Hafemeister C, et al. Identification of global alteration of translational regulation in glioma in vivo. PLoS ONE 2012;7:e46965.
4. Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, et al. Aberrant signaling pathways in glioma. Cancers 2011;3:3242-78.
5. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 2003;28:51-64.
6. Tan F, Thiele CJ, Li Z. Collapsin response mediator proteins: potential diagnostic and prognostic biomarkers in cancers (Review). Oncol Lett 2014;7:1333-40.
7. Oliemuller E, Pel-aez R, Garasa S, Pajares MJ, Agorreta J, Pío R, et al. Phosphorylated tubulin adaptor protein CRMP-2 as prognosticmarker and candidate therapeutic target for NSCLC. Int J Cancer 2013;132:1986-95.
8. Fukada M, Watakabe I, Yuasa-Kawada J, Kawachi H, Kuroiwa A, Matsuda Y, et al. Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J Biol Chem 2000;275: 37957-65.
9. Horiuchi M, Far el O, Betz H. Ulip6, a novel unc-33 and dihydropyrimidinase related protein highly expressed in developing rat brain. FEBS Lett 2000;480:283-6.
10. Ricard D, Rogemond V, Charrier E, Aguera M, Bagnard D, Belin MF, et al. Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. J Neurosci 2001;21: 7203-14.
11. Veyrac A, Reibel S, Sacquet J, Mutin M, Camdessanch-e J-P, Kolattukudy P, et al. CRMP5 regulates generation and survival of newborn neurons in olfactory and hippocampal neurogenic areas of the adult mouse brain. PLoS ONE 2011;6:e23721.
12. Honnorat J, Aguera M, Zalc B, Goujet C, Quach T, Antoine J, et al. POP66, a paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol 1998;57: 311-22.
13. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatr 2009;80:412-6.
14. Meyronet D, Massoma P, Thivolet F, Chalabreysse L, Rogemond V, Schlama A, et al. Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. Am J Surg Pathol 2008;32:1699-708.
15. Brot S, Malleval C, Benetollo C, Auger C, Meyronet D, Rogemond V, et al. Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. Eur J Cancer 2013;319:588-99.
16. Jauffred B, Llense F, Sommer B, Wang Z, Martin C, Bellaiche Y. Regulation of centrosome movements by numb and the collapsin response mediator protein duringDrosophila sensory progenitor asymmetric division. Development 2013;140:2657-68.
17. Purow BW, Haque RM, NoelMW, SuQ, Burdick MJ, Lee J, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005;65:2353-63.
18. Stockhausen M-T, Kristoffersen K, Poulsen HS. The functional role of Notch signaling in human gliomas. Neuro-oncology 2010;12:199-211.
19. Kristoffersen K, Villingshøj M, Poulsen HS, Stockhausen M-T. Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther 2013;14:625-37.
20. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33.
21. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28:17-28.
22. Cho S, Lu M, He X, Ee P-LR, Bhat U, Schneider E, et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A 2011;108:20778-83.
23. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastomamultiforme in a human astrocyte model of glioma. Cancer Res 2001;61:6674-8.
24. Zhao N, Guo Y, Zhang M, Lin L, Zheng Z. Akt-mTORsignaling is involved in Notch-1-mediated glioma cell survival and proliferation. Oncol Rep 2010;23:1443-7.
25. Li J, Cui Y, Gao G, Zhao Z, Zhang H, Wang X. Notch1 is an independent prognostic factor for patients with glioma. J Surg Oncol 2011;103:813-7.
26. Dell'albani P, Rodolico M, Pellitteri R, Tricarichi E, Torrisi SA, D'Antoni S, et al. Differential patterns ofNOTCH1-4 receptor expression are markers of glioma cell differentiation. Neuro-oncology 2014;16:204-16.
27. Krejci A, Bray S. Notch activation stimulates transient and selective binding of Su(H)/CSL to target enhancers. Genes Dev 2007;21:1322-7.
28. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligandinduced proteolytic release of intracellular domain.Nature 1998;393:382-6.
29. Diebold G, Ducray F, Henaine A-M, Frappaz D, Guyotat J, Cartalat-Carel S, et al. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. J Clin Pharm Ther 2014;39:642-8.
30. JarryM, Lecointre C, Malleval C, Desrues L, SchouftM-T, Lejoncour V, et al. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis. Neuro-oncology. 2014;16:1484-98.
31. Bocchini V, Casalone R, Collini P, Rebel G, Curto Lo F. Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblastoma multiforme. Cell Tissue Res 1991;265:73-81.
32. Yu H-P, Qi S-T, Feng W-F, Zhang G-Z, Zhang H-P, Tian J-J. Interference of Notch 2 inhibits the progression of gliomas and induces cell apoptosis by induction of the cell cycle at the G0/G1 phase. Mol Med Rep 2015;11: 734-8.
33. Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, et al. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010;1:822-35.
34. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
35. Rand MD, Grimm LM, Artavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol 2000;20:1825-35.
36. Balenci L, Clarke ID, Dirks PB, Assard N, Ducray F, Jouvet A, et al. IQGAP1 protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res 2006;66:9074-82.
37. Raghu H, Gondi CS, Dinh DH, Gujrati M, Rao JS. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor. Mol Cancer 2011;10:130.
38. Artavanis-Tsakonas S, RandMD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
39. Chastagner P, Israel A, Brou C. AIP4/Itch regulates Notch receptor degradation in the absence of ligand. PLoS ONE 2008;3:e2735.
40. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005;102: 5814-9.
41. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007;106:417-27.
42. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
43. Aster JC, Blacklow SC. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 2012;30:2418-20.
44. Sun P, Xia S, Lal B, Eberhart CG, Quinones-Hinojosa A, Maciaczyk J, et al. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 2009;27:1473-86.
45. Xu P, Qiu M, Zhang Z, Kang C, Jiang R, Jia Z, et al. The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo. J Neurooncol 2010;97: 41-51.
46. AguileraC, Hoya-Arias R, Haegeman G, Espinosa L, Bigas A. Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression. Proc Natl Acad Sci U S A 2004;101:16537-42.
47. Yamamoto S, Charng W-L, Bellen HJ. Endocytosis and intracellular trafficking of Notch and its ligands. Curr Top Dev Biol 2010;92:165-200.
48. Qiu L, Joazeiro C, Fang N, Wang HY, Elly C, Altman Y, et al. Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem 2000;275:35734-7.
49. Puca L, Chastagner P, Meas-Yedid V, Israël A, Brou C. a-arrestin 1 (ARRDC1) and b-arrestins cooperate to mediate Notch degradation in mammals. J Cell Sci 2013;126:4457-68.
50. Kageyama R, Niwa Y, Shimojo H, Kobayashi T, Ohtsuka T. Ultradian oscillations in Notch signaling regulate dynamic biological events. Curr Top Dev Biol 2010;92:311-31.
51. Williamson R, van Aalten L, Mann DMA, Platt B, Plattner F, Bedford L, et al. CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. J Alzheimer's Dis 2011;27:615-25.